PL3328844T3 - Pochodne sulfamidu 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i zawierająca je kompozycja farmaceutyczna - Google Patents

Pochodne sulfamidu 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i zawierająca je kompozycja farmaceutyczna

Info

Publication number
PL3328844T3
PL3328844T3 PL16830838T PL16830838T PL3328844T3 PL 3328844 T3 PL3328844 T3 PL 3328844T3 PL 16830838 T PL16830838 T PL 16830838T PL 16830838 T PL16830838 T PL 16830838T PL 3328844 T3 PL3328844 T3 PL 3328844T3
Authority
PL
Poland
Prior art keywords
inhibitor
pharmaceutical composition
same
histone deacetylase
sulfamide derivatives
Prior art date
Application number
PL16830838T
Other languages
English (en)
Polish (pl)
Inventor
Jaekwang Lee
Younghue HAN
Yuntae Kim
Jaeki Min
Miseon BAE
Dohoon Kim
Seokmin JIN
Jangbeen KYUNG
Original Assignee
Chong Kun Dang Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp. filed Critical Chong Kun Dang Pharmaceutical Corp.
Publication of PL3328844T3 publication Critical patent/PL3328844T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL16830838T 2015-07-27 2016-07-27 Pochodne sulfamidu 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i zawierająca je kompozycja farmaceutyczna PL3328844T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150106177 2015-07-27
PCT/KR2016/008218 WO2017018805A1 (en) 2015-07-27 2016-07-27 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP16830838.5A EP3328844B1 (en) 2015-07-27 2016-07-27 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
PL3328844T3 true PL3328844T3 (pl) 2020-07-27

Family

ID=57885712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16830838T PL3328844T3 (pl) 2015-07-27 2016-07-27 Pochodne sulfamidu 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i zawierająca je kompozycja farmaceutyczna

Country Status (21)

Country Link
US (1) US10464911B2 (enExample)
EP (1) EP3328844B1 (enExample)
JP (1) JP6538266B2 (enExample)
KR (1) KR101799005B1 (enExample)
CN (1) CN107980040B (enExample)
AU (1) AU2016299486B2 (enExample)
BR (1) BR112017027798B1 (enExample)
CA (1) CA2987570C (enExample)
DK (1) DK3328844T3 (enExample)
ES (1) ES2774510T3 (enExample)
HR (1) HRP20200280T1 (enExample)
HU (1) HUE048534T2 (enExample)
MX (1) MX376585B (enExample)
MY (1) MY194018A (enExample)
NZ (1) NZ736432A (enExample)
PH (1) PH12017501939B1 (enExample)
PL (1) PL3328844T3 (enExample)
PT (1) PT3328844T (enExample)
RU (1) RU2695227C9 (enExample)
TW (1) TWI694074B (enExample)
WO (1) WO2017018805A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291809B1 (en) 2015-05-07 2021-08-25 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2016179554A1 (en) 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
CA3001666C (en) 2015-10-12 2021-03-30 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
EP3661931A1 (en) 2017-07-31 2020-06-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102059027B1 (ko) * 2018-01-12 2019-12-24 주식회사 비엔에이치리서치 Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물
KR102316234B1 (ko) * 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP7470058B2 (ja) * 2019-01-30 2024-04-17 武田薬品工業株式会社 複素環化合物
ES2984772T3 (es) 2019-04-17 2024-10-31 Quimatryx S L Derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasas
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BR112021026334A2 (pt) 2019-06-27 2022-05-10 Medstar Health Macrófagos ativados por hdac6, composições, e usos dos mesmos
WO2021021979A2 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2020353984B2 (en) 2019-09-27 2025-09-25 Takeda Pharmaceutical Company Limited 2-isoindol-1,3,4-oxadiazole derivatives useful as HDAC6 inhibitors
CN114980887A (zh) 2019-12-20 2022-08-30 特纳亚治疗股份有限公司 氟代烷基-噁二唑及其用途
KR102537616B1 (ko) * 2020-02-25 2023-05-26 주식회사 종근당 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102537615B1 (ko) 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2022013728A1 (en) * 2020-07-14 2022-01-20 Chong Kun Dang Pharmaceutical Corp. Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
PE20231744A1 (es) 2020-08-07 2023-10-31 Italfarmaco Spa Nuevos inhibidores selectivos de hdac6 basados en oxadiazol
KR102685058B1 (ko) 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
KR102905373B1 (ko) * 2021-04-08 2025-12-29 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
WO2022235842A1 (en) * 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
EP4475845A4 (en) * 2022-02-08 2025-12-31 Univ Georgetown A1H-BENZO[C][1,2]THIADIAZINE-2,2-DIOXIDES BEARING HETEROCYCLIC BONDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS 6
KR102904231B1 (ko) * 2022-04-07 2025-12-29 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
EP4504190A4 (en) 2022-04-08 2026-03-25 Eikonizo Therapeutics Inc OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES
TW202412772A (zh) 2022-07-19 2024-04-01 義大利商義大利藥品股份有限公司 作為選擇性組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物
WO2024033293A1 (en) 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors
KR20240035172A (ko) * 2022-09-08 2024-03-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
TW202426439A (zh) * 2022-10-14 2024-07-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之磺醯亞胺化合物以及含彼之醫藥組合物
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1
WO2026018065A1 (en) * 2024-07-18 2026-01-22 Eurofarma Laboratórios S.A. Hdac-6 inhibiting compounds and treatment of diseases with the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276432A3 (de) 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
KR100265385B1 (ko) 1998-02-27 2000-11-01 윤여표 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2005509606A (ja) 2001-10-03 2005-04-14 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
ES2325205T3 (es) 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
WO2007032445A1 (ja) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2007107758A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd Antibacterial agents
US20070293530A1 (en) * 2006-06-14 2007-12-20 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
WO2008073509A2 (en) 2006-12-11 2008-06-19 Genentech, Inc. Compositions and methods for treating a neoplasm
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (ko) 2007-08-28 2009-06-19 전병태 소화기계 질환개선 및 예방용 식품 조성물
RU2010122324A (ru) 2007-11-02 2011-12-10 Момента Фармасьютикалз, Инк. (Us) Полисахаридные композиции, не обладающие антикоагулянтными свойствами
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US8440716B2 (en) * 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US20120136003A1 (en) 2009-04-20 2012-05-31 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
US8431538B2 (en) 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
WO2011088192A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
NZ601655A (en) 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
CN103108867A (zh) 2010-02-25 2013-05-15 皮拉马尔企业有限公司 噁二唑化合物及其制备和用途
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP3216798A3 (en) 2010-12-09 2017-10-25 Wockhardt Limited Ketolide compounds
KR101262870B1 (ko) 2011-01-28 2013-05-09 환인제약 주식회사 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素6選択的阻害剤
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
CA2850757A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
EP2785713B1 (en) 2011-11-28 2016-09-07 Novartis AG Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN103974956B (zh) 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
CA2866707A1 (en) 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
EP3385257A1 (en) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
EP3080125B1 (en) 2013-12-12 2018-10-10 Chong Kun Dang Pharmaceutical Corp. Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
CN104744446B (zh) 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN107108593B (zh) 2014-11-24 2020-03-24 美迪福伦Dbt有限公司 作为类香草素受体配体ii的基于取代的恶唑和噻唑的羧酰胺和脲衍生物
CN106349451B (zh) 2015-07-14 2020-11-13 罗门哈斯公司 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PL3328843T3 (pl) * 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
CA3001666C (en) 2015-10-12 2021-03-30 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
JP2018521092A (ja) 2018-08-02
CN107980040B (zh) 2021-11-26
CN107980040A (zh) 2018-05-01
US20180230113A1 (en) 2018-08-16
AU2016299486B2 (en) 2019-08-01
JP6538266B2 (ja) 2019-07-03
DK3328844T3 (da) 2020-03-02
ES2774510T3 (es) 2020-07-21
KR20170013186A (ko) 2017-02-06
TW201712007A (zh) 2017-04-01
PT3328844T (pt) 2020-03-04
WO2017018805A1 (en) 2017-02-02
EP3328844A4 (en) 2018-12-19
KR101799005B1 (ko) 2017-11-17
RU2695227C1 (ru) 2019-07-22
MY194018A (en) 2022-11-08
MX2017017090A (es) 2018-12-11
RU2695227C9 (ru) 2020-03-04
CA2987570A1 (en) 2017-02-02
EP3328844A1 (en) 2018-06-06
EP3328844B1 (en) 2019-11-27
BR112017027798B1 (pt) 2023-12-19
MX376585B (es) 2025-03-07
AU2016299486A1 (en) 2017-11-09
BR112017027798A2 (pt) 2018-08-28
NZ736432A (en) 2019-01-25
HK1251549A1 (zh) 2019-02-01
CA2987570C (en) 2021-06-15
US10464911B2 (en) 2019-11-05
HUE048534T2 (hu) 2020-07-28
TWI694074B (zh) 2020-05-21
HRP20200280T1 (hr) 2020-05-29
PH12017501939A1 (en) 2018-03-19
PH12017501939B1 (en) 2018-03-19

Similar Documents

Publication Publication Date Title
HUE048534T2 (hu) 1,3,4-oxadiazol-szulfamid-származékok hiszton deacetiláz 6 inhibitorként és ezt tartalmazó gyógyszerkészítmény
FI3328843T3 (fi) 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
PL3331864T3 (pl) Związki pochodne 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 oraz zawierająca je kompozycja farmaceutyczna
PT3362445T (pt) Compostos de derivado de oxadiazol amina como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
IL274973A (en) History of 4,2,1-oxadiazole as histone deacetylase inhibitors
EP3116859A4 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
HUE051537T2 (hu) 1,3,4-oxadiazolamid-származék vegyület mint hiszton deacetiláz 6 inhibitor és ezt tartalmazó gyógyszerkészítmény
HUE052749T2 (hu) Meloxicamot és rizatriptant tartalmazó gyógyászati készítmények
GEAP201914688A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IL247836A0 (en) 1, 3-benzodioxole derivatives, preparations containing them and their uses
PL2991982T3 (pl) Nowe związki dla selektywnych inhibitorów deacetylazy histonowej i zawierające je kompozycja farmaceutyczna
IL249020B (en) History of (n-(5-amino--1,3,4-thiadiazol-2-yl)-2-(methoxy/ethoxy)-2-phenyl-acetamide and pharmaceutical preparations containing them
PL3297992T3 (pl) Heterocykloalkilowe związki pochodne jako selektywne inhibitory deacetylazy histonowej oraz zawierające je kompozycje farmaceutyczne
EP3381925A4 (en) Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
EP3272742A4 (en) Histone deacetylase inhibitor, and preparation method and use thereof
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
EP3227293A4 (en) 6.7-cyclicmorphinan derivatives and use thereof
IL266659B (en) fgfr4 inhibitor, a pharmaceutical preparation containing it and its use
EP3153163A4 (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
HK40039295A (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors